Laleh Amiri-Kordestani, M.D. is a clinical team leader and cardio-oncology liaison at the FDA, CDER, Office of Hematology and Oncology Products. At the FDA, Dr. Amiri has focused on cardio-oncology and breast cancer oncology drug development. Dr. Amiri attended the University of Tehran Medical Sciences.

Moderator: Session 10 - Research Frontiers in Cardio-Oncology

She did a year of post-doctoral research fellowship in Molecular Genetics Laboratory at NIH and went on to study internal medicine at the Georgetown University/Washington Hospital Center and completed her medical oncology and hematology fellowship at the National Cancer Institute (NCI) in Bethesda, MD. In addition, she pursued an M.S. degree in Clinical Research in the Joint Program of the National Cancer Institute and Duke University. Under the direction of Dr. Sandra Swain, she became familiar with the design and implementation of oncology clinical trials and at the NCI she worked with Dr. Susan Bates focusing on early phase clinical trials. Dr. Amiri remains clinically active, treating breast cancer patients at NCI and practicing inpatient medicine at Georgetown University Hospital.

Dr. Saro Armenian, is an Associate Professor in the Departments of Pediatrics and Population Sciences, and is the Director of the Division of Outcomes Research at City of Hope. He is the immediate past Chair of the Children’s Oncology Group Survivorship and Outcomes Committee, and is a Leukemia & Lymphoma Society Clinical Research Scholar.

Conference Topic: Session 9 - Guidelines in Cardio-Oncology: Where are we now?

His own research focuses on understanding the pathophysiology and risk factors for cardiovascular complications such as therapy-related heart failure, coronary artery disease, and stroke in long-term survivors of childhood and adult-onset cancer. Dr. Armenian currently leads a multi-center NIH-funded randomized placebo-controlled clinical trial examining the efficacy and safety of carvedilol for heart failure risk reduction in childhood cancer survivors. In addition, he has a number of ongoing studies evaluating novel strategies for early screening and prevention of cardiovascular disease in cancer survivors, funded by the NIH, the St. Baldrick’s Foundation, American Cancer Society, and the Leukemia and Lymphoma Society.

Ana Barac, MD, PhD, is a noninvasive cardiologist at MedStar Heart and Vascular Institute and an Assistant professor of Medicine at Georgetown University. Her clinical and research interests focus on the mechanisms, diagnosis and treatment of cardiac complications of cancer therapies and she leads MedStar Heart and Vascular Institute’s Cardio-Oncology program.

Moderator: Session 2 - Thrombotic and Vascular Considerations in Patients with Cancer

Dr. Barac has basic science research background in signaling pathways and in vascular physiology research on endothelial function. She previously was a research fellow at the National Institute of Dental and Craniofacial Research, National Institutes of Health. She holds KL2 Scholar Award from the Georgetown-Howard Universities Center for Clinical and Translational Science for investigations of cardiovascular toxicity in patients with breast cancer. Her clinical cardiac imaging expertise includes advanced training in cardiac MR and echocardiography. Dr. Barac led the Cardio-Oncology Working group within the American College of Cardiology (ACC) and was appointed chair of the new ACC Cardio-Oncology Council in 2015. She serves on the editorial boards of the Journal of the American College of Cardiology (JACC), the Journal of Cardiovascular Translational Research and the Cardio-Oncology journal.

Dr. Blaes graduated from the University of Notre Dame and then received her M.D. degree from Loyola University Chicago, Stritch School of Medicine. She performed her residency at the University of Minnesota, where she was named the Resident Teacher of the Year and received the Gold Foundation Humanism and Excellence in Teaching Award for her outstanding contributions as a resident role model.

Conference Topic: Session 7 - Common risk factors between cancer and cardiovascular disease

She served as Chief Resident in Internal Medicine and then subsequently completed a Hematology and Oncology fellowship and a Master of Science in Clinical Research degree at the University of Minnesota, prior to joining the faculty. Dr. Blaes has a special interest in cancer survivorship, the late effects of cancer therapy, and medical education. Her research interests, funded by a BIRCWH award, include quality of life, cardiac complications of chemotherapy, and the late effects of cancer therapy in cancer survivors, particularly breast and colorectal cancer survivors. In addition to mentoring medical students and residents on research projects, she teaches the Blood pathophysiology course and the Human Diseases IV course within the medical school. She received an Educational Excellence Award from the Department of Medicine in 2010, and has been named to Minnesota Monthly’s Best Doctors for Women in 2011 and 2012.

[Watch Presentation]

Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Division Head of Hematology / Oncology at St. Michael’s Hospital in Toronto and is the Head of the Oncology Clinical Research Group there. She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Assistant Professor at the University of Toronto.

Moderator: Session 5 - Hematology/Oncology: Treatment modifications to manage cardiovascular toxicity

She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region. She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research. Her main area of clinical research is cardiotoxicity from cancer therapy and is the Co-Chair of the annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is active in research, education and has been instrumental in the clinical development of the cancer program at St. Michael’s Hospital.

Dr. Joseph Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. His clinical practice is in the subspecialty of Cardio-oncology.  

Conference Topic: Session 11 - Cardio-Oncology Fellowship Training: What does the future hold?

He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012. He is one of the Founding Editors of Cardio-oncology Journal. 

[Watch Presentation]

Paul Cohen, MD, PhD runs a basic science laboratory at the Rockefeller University and is a consultant cardiologist at Memorial Sloan Kettering Cancer Center. Dr. Cohen's research group applies basic and translational approaches to explore the links between obesity and associated diseases including diabetes, hypertension, and cancer.

Conference Topic: Session 7 - Metabolic Issues in Cardio-Oncology

Dr. Cohen is a graduate of the Tri-Institutional MD-PhD program. He completed a residency in Internal Medicine at Columbia University Medical Center and a fellowship in Cardiology at Brigham and Women’s Hospital.

[Watch Presentation]

Dr. Cornell is an assistant professor of medicine. He received a B.S. in clinical laboratory science from Saint Louis University and then worked in clinical and molecular hematology at Johns Hopkins Hospital. He attended medical school at Trinity College in Dublin, Ireland. Dr. Cornell then completed his Internal Medicine Residency and Hematology/Oncology Fellowship at The Medical College of Wisconsin.      

Conference Topic: Session 5 - Cardiac Considerations for Plasma Cell Disorders

He obtained his Master's in Clinical and Translational Science. He specializes in the treatment of plasma cell disorders including Multiple Myeloma, Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), POEMS syndrome, Amyloid Light-Chain (AL) Amyloidosis, Plasma Cell Leukemia, Solitary Plasmacytoma and Waldenstrom Macroglobulinemia. Dr. Cornell's research focuses on translational and early phase clinical trials for the treatment of multiple myeloma. He also conducts research and clinical trials for relapsed/refractory multiple myeloma and other plasma cell disorders. He also researches cardio-oncology to better understand the effects of chemotherapy on the heart and vascular system. Dr. Cornell is an active member of the American Society of Hematology, American Society of Clinical Oncology, International Society of Cardio-Oncology, and the American Society for Blood and Marrow Transplantation. He is a member of the multiple myeloma subcommittee of ASBMT.

I am a board-certified medical oncologist and work as part of a multidisciplinary team to care for patients with breast cancer. In my clinical research I focus on developing more-effective and less-toxic treatment strategies for women with this disease. My particular interest is in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer.  

Conference Topic: Session 1 - Are anthracyclines relevant for breast cancer in 2016?

My research has changed standard practice. For example, the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer was a direct consequence of an investigator-initiated trial that I led at Memorial Sloan Kettering. Additionally, I led another investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer. This led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. I am currently leading other research trials, both locally and internationally. From these studies and others, I have also focused on the unique cardiac toxicities of anthracyclines and anti-HER2 agents.  New therapies have greatly improved the prognosis for many breast cancer patients, but some treatments produce side effects that appear years after the completion of treatment. My colleagues and I are working to develop markers or predictors to identify the patients who may be at risk of developing early, and possibly late, complications such as heart damage so that we can design early interventions to prevent these side effects — for example, by adding a cardiac drug to treatment to minimize heart problems in the future.

Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul’s Hospital, a Clinical Assistant Professor at the University of British Columbia, and Director of the UBC Cardiology-Oncology Program. She obtained her Bachelor of Science in Physiology at McGill University before attending medical school at the University of British Columbia.

Conference Topic: Session 1 - Do cardiovascular preventive strategies work during chemotherapy?

Moderator: Session 6 - Poster Presentations

She stayed at UBC for her Internal Medicine residency and Cardiology fellowship. She then completed fellowships in Advanced Heart Failure & Transplant Cardiology and Cardio-Oncology & Cardiac Amyloidosis at Stanford University School of Medicine. She is a candidate for a Masters of Science in clinical epidemiology at the Harvard School of Public Health. Her research interests are focused on the prevention, diagnosis, and management of heart disease related to cancer therapy and the epidemiology of heart disease in cancer survivors. She also has interests in cardiac amyloidosis and advanced heart failure.

Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Associate Professor in the Department of Medicine at the University of Ottawa.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group.

Moderator: Session 1 - Contemporary Breast Cancer Therapy

Conference Topic: Session 11 - Opportunities for collaboration, research and education

She is the research lead for the breast disease site group at the Ottawa Hospital Cancer Centre, and a member of the IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group. Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the founder of the Ottawa Cardiac Oncology Program as well as the Canadian Cardiac Oncology Network, organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.

[Watch Presentation]

Dr. Durand is the Medical Director of Cardiomyopathy Services, Director of Cardiovascular Genetics Research, and the Director of the Cardiology Fellowship Program at the University of Texas MD Anderson Cancer Centre, in Houston, TX. He is also a Clinical Assistant Professor of Medicine at the Baylor College of Medicine, Staff Physician of the Heart Failure/Heart Failure Transplant Service at St. Luke’s Episcopal Hospital, and the Founder of the worlds first heart failure program dedicated to cardiotoxicity and cancer.

Moderator: Session 3 - Debate

His major research is dedicated to understanding the molecular genetics of cardiomyopathies, primarily the identification of genes responsible for cardiomyopathy of all etiologies. His work also focuses on defining the molecular mechanisms involved in chemotherapy-induced cardiomyopathy. Limited studies have been conducted to define the genetic basis of why patients undergoing cancer treatment develop heart failure and respond to standard medical therapy for treatment of heart failure. Dr. Durand has established the worlds largest database of DNA from patients with heart failure secondary to chemotherapy and have future plans to perform genotyping to identify heart failure susceptibility genes which may predispose patients to development of left ventricular dysfunction and potentially response and recovery of cardiac function. To this date they now have over 600 samples and have plans on obtaining 3000 samples. In addition, he has also developed a tissue bank for further expression studies to identify critical pathways which are common to cancer biology and cardiovascular biology. Dr. Durand's areas of scientific interests also includes genotyping single nucleotide polymorphisms of Tyrosine Kinase Inhibitor-related cardiomyopathy, and acute coronary syndromes in cancer patients with Thrombocytopenia.

Barbara has over 25 years of acquired experience in nursing, health care services and leadership. Her experience in the health care system has included significant outcomes related to advanced practice, inter-professional collaboration and education, culture transformation and innovative models of care.

Moderator: Session 9 - Long-Term Management in Primary Care

Dr. Nina Ghosh obtained her medical degree from the University of Western Ontario and completed Internal Medicine Residency at the University of Toronto and Cardiology Residency at the University of Ottawa Heart Institute. She subsequently completed a 3 year combined fellowship in Heart Failure / Cardiac Transplantation and Advanced Cardiovascular Imaging at Harvard Medical School in 2014.  

Conference Topic: Session 9 - Long-Term Management: Is there a role for the cardiologist and primary care physician in the community?

Dr. Ghosh has had a longstanding interest in Cardio-Oncology. She undertook training in this field as part of her Heart Failure Fellowship at Harvard Medical School through their Cardio-Oncology Program, a joint collaboration of the Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston. She aspires to provide a collaborative community-based cardiovascular health option to cancer patients with the goals of prevention, early detection and treatment of cancer treatment-related cardiotoxicity and long-term post treatment surveillance for delayed toxicity.

Dr. Pamela Goodwin has been actively involved in research relating to host factors in breast cancer for the past 25 years. Early in her career, she became intrigued with the possibility that host (patient-related) factors, especially obesity, might impact outcomes of women diagnosed with breast cancer. She began a program of research that has focused on the role of these factors, including obesity, nutrition, exercise and related factors in the clinical course of breast cancer.

Conference Topic: Session 7 - Obesity is a leading cause of cancer death

She has led a number of studies which investigate the complex interactions between body size, nutrition, exercise and physiologic mediators such as insulin, IGF-I and vitamin D, examining the impact of these factors on risk and survival of women diagnosed with breast cancer. Dr. Goodwin has expanded this work to investigate the status of long-term breast cancer survivors and the influences of hereditary factors, vitamin D and metformin on breast cancer outcomes. She currently leads a large international Phase III trial (NCIC MA.32) which examines the impact of an insulin lowering drug, metformin, on breast cancer outcomes and has an active translational research program examining the interface between host factors and tumor biology in both early and advanced breast cancer. She leads the Hold’Em for Life Translating Research Discoveries into Breast Cancer Cures Program at Mount Sinai Hospital and the Princess Margaret Cancer Centre. Dr. Goodwin is a Professor of Medicine at the University of Toronto, with cross appointments in the Department of Health Policy, Management and Evaluation and in the School of Graduate Studies. She is a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Director of the hospital's Marvelle Koffler Breast Centre and holder of the Marvelle Koffler Chair in Breast Research. Dr. Goodwin is an Associate Editor of the Journal of Clinical Oncology, the leading clinical oncology journal in the world, and she has published over 180 research articles in leading journals. She is also active in the clinical management of breast cancer patients.

Dr. Harrison is currently the National Director of Advanced Cardiac Imaging of Iasi Healthcare Inc .  which owns and operates 15 acute care hospitals in  Florida, Texas, Louisiana,  Utah, Arizona, and Nevada. Dr. Harrison was one of first to use the therapeutic hypothermia for Cardiac Arrest patients. He began to use this treatment clinically shortly after the landmark articles were published in February 2002.

Conference Topic: Session 4 - Role of CT, CAC and Nuclear Imaging in Cardio-Oncology

He is currently integrating hypothermic medicine into the IASIS healthcare system. He has served as a consultant for many national companies associated with cardiac imaging. Dr. Harrison started and directs the Joint Memorial Hospital / University of South Florida Medical School Advanced Cardiac Imaging Program for practicing  physicians , cardiac fellows, and medical student training. He is a preceptor for the University of South Florida Medical School and Saba University Medical School of the  Netherland Antilles. Dr. Harrison received his medical degree from the University of Kentucky and completed internship, Internal Medicine residency and Cardiology Fellowship at the University of South Florida  where he was a Special Fellow of the Florida Heart Association. He was acting Director of the Cath Lab at the VA Hospital  for 3 month prior to finishing his training. He is a founding physician of the University of South Florida Medical School. Dr. Harrison's experience in cardiology covers a broad spectrum. He was co-director of the Cardiology Center at Tampa General Hospital for thirteen years and directed noninvasive cardiology for seven years where he started echocardiography and nuclear cardiology. At Tampa General he performed over 14,000 heart catheterizations, numerous coronary angioplasties, cardiac electrophysiologic studies and myocardial biopsies and was a transplant cardiologist on the transplant team for three years. His first transplant patient has survived  over 20 years. He and his colleagues started the first outpatient cardiovascular health center in Tampa at Memorial Hospital where he is currently the Medical Director and where he has directed the cardiac rehabilitation program. His non-invasive cardiology interests are 3D echo, multislice CAT scan imaging of the coronaries, Cardiac PET/CT, Cardiac MRI, and hybrid imaging.

Zaza Iakobishvili is a director of Emergency Cardiology Services and Cardio-oncology clinic at the Beilinson hospital in Rabin Medical Center, Petah Tikva. He received his medical degree in 1988 from the Tbilisi State Medical University and completed his postdoctoral training in Tbilisi Institute of Human Physiology. In 1996 he immigrated to Israel, completed 2-year residency in Internal medicine and received Board certification in Internal medicine after successful completion of qualifying examinations.  

Moderator: Session 9 - Long-Term Management in Primary Care

He applied to cardiology fellowship in the Department of Cardiology, Rabin Medical Center and successfully passed Board certification examinations in cardiology in 2001. He worked as attending physician in the cardiac intensive care unit from 2002 till 2009 when he was appointed to lead Emergency Cardiology Services. In 2008-2010 was appointed to the secretary of National Cardiology Board examination committee. From 2009 he is a secretary of Biennial International Meeting on Acute Cardiac Care. From 2011 he was elected secretary of Israel working group on Acute Cardiac Care. From 2015 he serves elected chairman of the working group on Acute Cardiac Care in Israel Heart Society. Zaza Iakobishvili is actively engaged in teaching at the Sackler Faculty of Medicine at the University of TelAviv, repeatedly named among “best teachers” of the University. He is actively involved in scientific process and is author and co-author of more than 60 papers and book chapters, published in peer-reviewed journals in the field of cardiology as Am Heart J, Am J Cardiol, Int J Cardiol, etc. He is the author of chapters on cardiogenic shock in European Society of Cardiology Textbook on Acute Cardiac Care (2010), Medical Clinics of North of America, American Heart Association book on cardiogenic shock (2011). He presents on international medical meetings as invited faculty of ESC in 2007, ESC Acute Cardiac Care meeting in Copenhagen, 2010, Madrid, 2013, Vienna, 2015. In 2015 he presented on Joint Israel-France association of cardiology meeting “Biomarkers of Cardiotoxicity”. Now he takes active participation in the European Society of Cardiology Acute Cardiac Care Association working group on quality of acute care. He leads Acute Coronary Syndrome Israeli Registry (ACSIS). In 2016 ACSIS will be accomplished by prehospital data from MDA (“Magen David Adom” Israel largest emergency medical system), as well as by patient-level follow-up data from health management organizations database thus allowing for the first time to follow the individual patient from the beginning of ACS until the chronic phase and outpatient management. Main fields of scientific interest are: cardio-oncology, epidemiology of cardiotoxicity of anti-cancer therapy, prevention and treatment of cardiotoxicity, cardiogenic shock, acute coronary syndromes and acute heart failure, diabetes treatment in cardiac patients, cardiac biomarkers. In 2013 he established and leads the clinic of cardio-oncology where more than 1000 patients with cancer and heart problems are getting follow-up and treatment. Now he is organizing Israel registry on cancer treatment cardiotoxicity supported by the grant from Israel Association of Cardiovascular Trials.

Dr. Johns is a manager of one of the oncology clinical drug review divisions within Health Canada. Over the past decade, she and her team have been responsible for recommendations for market authorization in Canada of numerous pharmaceutical products for the treatment of cancer. Karen has previously worked as a clinical reviewer of anti-cancer and anti-infective pharmaceutical drugs at Health Canada, and as a general practitioner within family medicine and oncology, and she has a Master of Science degree in Clinical Epidemiology.

Conference Topic: Session 10 - Regulatory Concerns and Pre-Clinical Testing in Cardio-Oncology

Conference Topic: Session 2 - Novel Oral Anticoagulants

Dr Lee was Principal Investigator of the CLOT and CATCH trials, evaluating the use of low molecular weight heparin for the long‐term treatment of cancer‐associated thrombosis. She sits on clinical practice guideline committees with the American Society of Clinical Oncology and the American Society of Hematology, and served as Chair of the Subcommittee on Hemostasis & Malignancy with the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. She is a member of the Guidelines and Protocols Advisory Committee to the Medical Services Commission of British Columbia.

[Watch Presentation]

Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.

Conference Topic: Live-Stream Session - Cardio-Oncology: Can we make a difference?

Conference Topic: Session 11 - Opportunities for collaboration, research and education

His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc. As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

[Watch Presentation]

Teresa López-Fernández, MD, is a noninvasive cardiologist in the Cardiac Imaging Unit and Cardio-Oncology Unit, at La Paz University Hospital, Madrid, Spain. Her clinical and research focus include the mechanisms, diagnosis and treatment of cardiac complications of cancer therapies. Her clinical cardiac imaging expertise includes advanced training in echocardiography, 3D echocardiography, and stress echocardiography.  

Moderator: Session 8 - Oral Abstract Presentations

Dr. López-Fernández is a member of the Spanish Society of Cardiology Cardiac Imaging Board and Cardio oncology working group board. She is also a Task Force Member for the development of a position paper on anticancer treatments and cardiovascular toxicity developed under the auspices of the Committee for Practice Guidelines of the European Society of Cardiology. Dr. López-Fernández obtained her degree in Medicine and Surgery in from the Universidad Complutense de Madrid (Spain) in 1996, followed by an I.R. Residence in Cardiology in the Hospital Fundación Jiménez Díaz, in Madrid (1997-2002). In 2004, she obtained her accreditation in advanced Echocardiography by the Spanish Society of Cardiology. Dr. López-Fernández completed additional certifications in Adult Transthoracic Echocardiography (2013) and Adult Transesophageal Echocardiography (2014) by the European Society of Cardiology.

Gary H. Lyman MD, MPH, is Co-Director of the Hutchinson Institute for Cancer Outcomes Research and Member of the Public Health Sciences and Clinical Research Divisions at the Fred Hutchinson Cancer Research Center. He is also Professor of Medicine as well as Professor in the Schools of Public Health and Pharmacy at the University of Washington.

Conference Topic: Session 2 - Thrombotic and Vascular Considerations in Patients with Cancer

Dr Lyman received his undergraduate and medical degree from the State University of New York in Buffalo and completed his Internal Medicine Residency at the University of North Carolina in Chapel Hill and Hematology/Oncology Fellowship at the Roswell Park Memorial Institute. Dr Lyman subsequently pursued a Postdoctoral Fellowship in Biostatistics at the Harvard School of Public Health and the Dana Farber Cancer Center. After joining the faculty of the University Of South Florida College Of Medicine, Dr Lyman served as Assistant, Associate and then full Professor of Medicine and Director of Medical Oncology. Shortly after his arrival, Dr Lyman began working with Lee Moffitt and leadership of the University to develop plans for the eventual H Lee Moffitt Cancer Center and Research Institute where he served as the founding Chief of Medicine and Director of the Division of Medical Oncology as well as Associate Chairman of the Department of Medicine at USF. During this period, he also served as Professor of Medicine and Professor of Epidemiology and Biostatistics at the University of South Florida. Upon leaving the Moffitt in 2000, Dr Lyman has held positions as Thomas Ordway Endowed Professor of Medicine and Cancer Center Director at the Albany Medical College and subsequently Professor of Medicine, Associate Cancer Center Director and Director of Health Services and Outcomes Research at the University of Rochester and Strong Memorial Hospital. Prior to relocating to his present position, Dr Lyman served as Professor of Medicine and Director of Comparative Effectiveness and Outcomes Research-Oncology at Duke University and the Duke Cancer Institute and a Senior Fellow at the Duke Center for Clinical Health Policy Research. Dr Lyman is active with the American Society of Clinical Oncology serving recently on the ASCO Board of Directors, co-Chairing of the Breast Cancer and Survivorship Guideline Advisory Groups as well as chairing the Guideline Methodology Committee and several individual guidelines including those related to Prevention and Treatment of Venous Thromboembolism in Cancer, Sentinel Node Biopsy in Early-Stage Breast Cancer and Melanoma, Use of Antiemetics in Patients Receiving Cancer Chemotherapy and Appropriate Chemotherapy Dosing in Obese Patients with Cancer. Dr Lyman has also a member of the Value of Cancer Care Task Force and Cancer Research Committee along with several additional roles within the Society. In 2010 Dr Lyman received the ASCO Statesman Award. He is also active in the American Society of Hematology, American Association for Cancer Research and the Institute of Medicine. Dr Lyman is Editor-In-Chief of Cancer Investigation and on the Editorial Board of the Journal of Clinical Oncology, the Journal of Global Oncology and several other specialty journals. In addition to serving as a Fellow of ASCO, Dr Lyman is a Fellow of the Royal College of Physicians (Edinburgh), the American College of Physicians, and the American College of Preventive Medicine. His research interests include precision medicine based on personalized cancer treatment and supportive care, comparative effectiveness and outcomes research related to biomarkers and targeted therapies, mathematical and statistical prognostic and predictive models, advanced methods of evidence synthesis in support of clinical practice guidelines and population studies of patterns of cancer treatment and the impact of health disparities on the quality of cancer care. Dr Lyman has authored or edited more than 15 books and nearly 600 articles in the scientific literature.

Dr. Alexander Lyon is a British Heart Foundation Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. He studied medicine at Oxford University where he gained a first class degree, and studied for his PhD thesis in myocardial gene therapy at Imperial College London.

Moderator: Session 5 - Hematology/Oncology: Treatment Modifications to Manage Cardiovascular Toxicity

He continued his gene therapy research during a postdoctoral research year in the laboratory of Roger Hajjar at Mount Sinai Hospital in New York. His clinical interests are in the field of heart failure, cardio-oncology and Takotsubo syndrome, and he is the theme leader for heart failure research in the NIHR-funded Biomedical Research Unit at the Royal Brompton Hospital. He is the clinical lead for the new Cardio-Oncology service at the Royal Brompton hospital, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. He is the president of the British Cardio-Oncology Society and a member of the European Society of Cardiology Taskforce on Cardio-Oncology. He is the clinical advisor to the british cancer patient charity Macmillan Cancer and helped to write the first patient information leaflet – Heart health for Cancer Patients. He is the UK national lead investigator for two gene therapy trials for chronic heart failure (CUPID2 and SERCA-LVAD), and is the heart failure lead for the RDN-HFpEF study assessing the role of renal sympathetic denervation for individuals with heart failure with preserved ejection fraction. He is leading both a laboratory research programme understanding the influence of stress and high catecholamine levels upon myocardial function, and he is coordinating both a national and European strategy to advance knowledge and improve care for individuals with Takotsubo syndrome. He runs a specialist clinic for patients with Takotsubo syndrome focussing on risk prediction and management of refractory symptoms.

Dr. Michael Mauro is a board-certified hematologist, professor, and leader of the Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center in New York City. After receiving his BS and MD from Dartmouth College and Dartmouth Medical School in New Hampshire, he completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan.

Moderator: Session 2 - Thrombotic and Vascular Considerations in Patients with Cancer

Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years, where he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. He holds positions on the boards of the International CML Foundation, the MAX Foundation, and the Leukemia and Lymphoma Society.

[Watch Presentation]

Conference Topic: Session 10 - NIH/NCI partnerships and funding opportunities

Dr. Minasian initiated and leads the NCI’s Community Cardiotoxicity Task Force, a working group of oncology clinical investigators, cardiology experts, NCI, NHLBI and FDA staff. Dr. Minasian participates in the NCI’s Women’s Cancer Clinic seeing patients, supervising fellows and participating in the development and implementation of clinical trials using novel agents. Prior to working for the NCI, NIH, Dr. Minasian was the Chief of the Hematology and Oncology Branch at the Augusta Veteran’s Administration Medical Center. She earned a Medical Degree from the George Washington University School of Medicine in Washington, D.C. She completed a fellowship in Medical Oncology at the Memorial Sloan‐Kettering Cancer Center.

[Watch Presentation]

Giorgio Minotti is Professor of Pharmacology, Head of Drug Sciences and Clinical Pharmacology, Chief of Clinical Trial Center, at the University Campus Bio-Medico of Rome. He earned his degrees in Medicine and Oncology at the Catholic University School of Medicine in Rome. He was fellow of the Italian Association for Cancer Research, Fulbright Scholar and Fulbright Visiting Professor at the Departments of Biochemistry, Michigan State University, East Lansing, MI, and Physiology and Biophysics, Case Western Reserve University, Cleveland, OH.

Moderator: Session 8 - Oral Abstract Presentations

He has authored some 90 papers in Medline-based journals, mostly focusing on pharmacokinetics, pharmacodynamics, and clinical correlates of anticancer drugs cardiovascular toxicity. He edited books for Wiley and Sons Ltd. (Cardiovascular toxicity of non cardiovascular drugs, 2010), and guest-edited special issues of Cell Biology and Toxicology, Cardiovascular Toxicology, and article series for Chemical Research in Toxicology. He is Editor-in-Chief of Chemotherapy, Deputy Editor of the newly founded Journal, Cardio-Oncology, Associate Editor of Cardiovascular Toxicology, member of the Editorial Board of Chemical Research in Toxicology, Journal of Pharmacology and Experimental Therapeutics, Journal of Regenerative Medicine. He is member of the Italian Societies of Pharmacology and Toxicology, American Society for Clinical Oncology, International Cardio-Oncology Society. His work has been awarded by Italian Associaton for Cancer Research, Italian Reasearch Council, Academic Press Inc., NATO Scientific Affairs Division, Southern Europe New Drugs Organization. He organized and chaired international meetings or workshops for the European Society of Toxicology, the European Society of Cardiology, Menarini International Foundation.

Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital.

Moderator: Session 7 - Prevention in Cardio-Oncology

Moderator: Session 10 - Research Frontiers in Cardio-Oncology

Following the completion of clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis (formation of new blood vessels) in heart disease. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School with a clinic and research program focused on the cardiovascular care for cancer patients and cancer survivors. In 2014, he joined Vanderbilt. Dr. Moslehi is an expert clinician on the management of cardiac complications associated with radiation and both novel and traditional chemotherapies. His clinic and research program is focused on the mechanisms of toxicities associated with novel targeted therapies and how this knowledge can be modulated to understand human cardiovascular biology.

Moderator: Session 1 - Contemporary Breast Cancer Therapy

Conference Topic: Session 9 - Role of the multidisciplinary team in cardio-oncology: bridging transitions in care

Dr. Juan Carlos Plana Gomez  is Chief of Clinical Operations of the Section of Cardiology, Department of Medicine at Baylor College of Medicine, Director of the Cardio-Oncology Center, and co-Director of the Center for Advanced Cardiac Imaging at Baylor St. Luke’s Medical Center. He is the Don W. Chapman Chair in Cardiology and tenured Associate Professor of Medicine. Dr. Plana is board certified in Cardiology and Echocardiography.

Debater: Type 1 / Type 2 Cardiotoxicity is not nonsense

Dr. Plana earned his medical degree from Pontificia Universidad Javeriana, Santafé de Bogotá (Colombia). His extensive training included internship, residency, chief resident year and fellowship in Cardiovascular disease and Cardiac Imaging (echocardiography and Nuclear Cardiology) at Baylor College of Medicine. Dr. Plana’s academic career started at the University of Texas MD Anderson Cancer Center where he served as Director of Cardiac Imaging and Medical Director of the Echocardiography laboratory. In 2010, he was recruited to Cleveland Clinic, where he opened as served as Co-Director of the Cardio-Oncology center. Dr. Plana's clinical and research interests include Cardio-Oncology, valvular heart disease, diseases of the aorta, and advanced cardiac imaging. The major focus of Dr. Plana’s clinical and scholarly interest is the development and application of novel echocardiographic techniques in the early detection of cardiac dysfunction caused by chemotherapeutic agents. His work has led to 38 reports published in the peer-reviewed literature, as well as 8 invited reviews and book chapters. He authored the Expert consensus for multi-modality Imaging evaluation of cardiovascular complications of radiotherapy in adults, and more recently chaired the Expert consensus for the multi-modality Imaging evaluation of adult patients during and after cancer therapy: a joint effort of the American Society of Echocardiography and the European Association of Cardiovascular Imaging. His national and international stature in the field of Cardio-Oncology and cardiac imaging is reflected by his 122 invited presentations at national and international conferences; his invited service to 5 journal editorial boards (including his current service to the International Board of the Journal of Cardiovascular Echocardiography); and his invited service to, and leadership of multiple committees of the American Society of Echocardiography (for which he currently serves on the Board of Directors) and other professional societies (representing the United States on the Echocardiography Section of the Inter-American Society of Cardiology) , as well as to the NIH (NCI/NHLBI) (member of the Expert Panel on Cardio-toxicity) and the FDA. In addition to his scholarly efforts, Dr. Plana has been a dedicated educator, having received major teaching awards from BCM (Excellence in Teaching Award, 2000), M.D. Anderson Cancer Center (Teacher of the Year Award, Section of Cardiology, U. Texas Health Science Center, 2007), and the Cleveland Clinic (Teacher of the Year Award, Department of Cardiovascular Medicine, 2011).

Dr Plummer is a consultant cardiologist at the Freeman Hospital in Newcastle upon Tyne. His clinical work focuses on cardiac implantable electronic device therapies but he also has a major clinical and research interest in cardiovascular effects of cancer treatments. He has co-written cardio-oncology guidance in 3 areas, given advice on more than 50 clinical trials and co-founded the British Cardio-Oncology Society in 2014 where he is Secretary and wrote/published BC-OS.org.

Conference Topic: Session 5 - Cardiovascular Effects of ADT in Prostate Cancer Patients

He trained in Bristol where he gained a PhD, St John's College Oxford where he completed his medical degree and in Newcastle where he undertook cardiology training. He is also involved in medical education from interviewing medical students to being the cardiology training programme director in the North East and serving on the exam board for the European General Cardiology Examination.

[Watch Presentation]

Dr. Sarosiek received his PhD in Molecular and Cellular Pharmacology from the University of Miami School of Medicine where he studied cancer therapeutics under the mentorship of Izidore Lossos, MD. Afterwards, he joined the laboratory of Anthony Letai, MD, PhD, at the Dana-Farber Cancer Institute and Harvard Medical School.  

Conference Topic: Session 10 - Why children are at risk for cardiotoxicity

During his postdoctoral studies, Dr. Sarosiek characterized how cell death is regulated in tissues during normal postnatal development as well as during the process of malignant transformation. Dr. Sarosiek now leads a cell death and cancer therapeutics laboratory at the Harvard T. H. Chan School of Public Health. The long-term goal of his laboratory is to develop a better understanding of how cell death is regulated in healthy and diseased cells in order to expose novel opportunities for therapeutic intervention.

Jessica Scott, PhD, is a Senior Scientist in the Exercise Physiology and Countermeasures Laboratory at NASA Johnson Space Center. She received her MSc and PhD in Cardiovascular Physiology at the University of British Columbia in Vancouver, Canada, and completed her Post-doctoral Fellowship at NASA Johnson Space Center in Exercise Physiology in Houston, Texas.    

Conference Topic: Session 7 - Accelerated Cardiovascular Disease in Cancer Patients and the Cardioprotective Role of Exercise

The acute physiological consequences of spaceflight and cancer therapy are surprisingly similar. Dr. Scott’s research is focused on: (1) evaluation and characterization of spaceflight and cancer-therapy induced cardiovascular phenotypes using novel exercise testing, imaging, and biomarker techniques, and (2) the efficacy of exercise training to prevent and/or reverse dysfunction. She is the recipient of Natural Sciences and Engineering Council of Canada Awards, Michael Smith Foundation for Health Research Awards, NASA’s Human Research Program Peer Award, NASA’s Innovation Achievement Award for the design and implementation of a novel ultrasound technique to measure muscle mass in microgravity, and NASA’s Group Achievement Award as a member of the One Year Mission Operations Team.

Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver. She completed her residency training in Toronto, and completed a fellowship in Locally Advanced Breast Cancer at Princess Margaret Hospital in Toronto. She also completed a Master’s in Clinical Epidemiology at University of Toronto. She is a Clinical Assistant Professor at the University of British Columbia in the Faculty of Medicine.

Conference Topic: Session 1 - Novel Breast Cancer Therapy

Moderator: Session 11 - Future Direction

She is past Chair of the Locally Advanced Breast Cancer Canadian National Consensus group, and has a strong research interest in this area. In July 2014 she took on the role of Clinical Skills Course Director in the undergraduate medical program at UBC.

[Watch Presentation]

Dr. Straatman is currently a cardiologist in the cardio-oncology and cardiac failure clinics at Vancouver General Hospital in Vancouver Canada. She is also the medical lead for adolescent transition at the British Columbia Children's Hospital in addition to being a clinical assistant professor in the Divisions of Internal Medicine, Paediatrics and Adolescent Medicine.  Dr. Straatman trained in cardiology, heart failure and cardiac transplantation at the University of Michigan and University of Toronto.

Conference Topic: Session 9 - Pediatric Survivors: The transition to adult cardiovascular medicine

She has conducted research in the area of adolescent transition and is currently engaged in a project with the Doctors of BC to explore the barriers to transition for cardiac patients and create transition care management plans.

Dr. Paaladinesh Thavendiranathan MD, MSc SM, FRCPC, FASE is a cardiologist at the Toronto General Hospital, University of Toronto. He is an assistant professor of medicine and a clinician investigator.  His training was in advanced cardiovascular imaging and his current clinical practice involves work with cardiac MRI, CT, and echocardiography.

Conference Topic: Session 4 - 2D/3D strain imaging and the role of 3D echocardiography

He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention which focuses on cardiac toxicity from systemic therapies including cancer therapy. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity.

[Watch Presentation]

Dr. Virani is a key opinion leader for heart failure in Canada. He is founding Director of the Heart Failure Program at Vancouver General Hospital, Regional Director of Heart Failure Services for Vancouver Coastal Health/Providence Health Care, Heart Failure Physician Lead at Cardiac Services BC and Clinical Associate Professor of Medicine at the University of British Columbia.

Moderator: Session 11 - Future Direction

He completed his internal medicine and cardiology training at UBC before embarking on a sub-specialization in heart failure and cardiac transplantation at Stanford University. He also has a Master’s degree in Public Health from Columbia University with a focus on healthcare management. His professional interests include public policy related to health care delivery with specific reference to healthcare systems redesign and quality in the Canadian context. Dr. Virani has authored a number of papers on chronic and acute decompensated heart failure and is a principal investigator on numerous research trials. He holds peer reviewed grant funding as a principal or co-investigator in excess of $1 million. He serves on the Provincial Advisory Committee for Cardiac Health, the executive of the Canadian Heart Failure Society, the Canadian Heart Failure Guidelines Committee and Co-Chairs British Columbia’s Specialist Services Committee.

Dr Mark Westwood was educated at St John’s College, Oxford and St Bartholomew’s Hospital, London. His interest in cardiac MRI (CMR) started in 2001 with his thesis of CMR. He was appointed as a Consultant Cardiologist at the London Chest Hospital in 2008 where he was lead clinician for CMR.

Conference Topic: Session 4 - Role of CMR in cardio-oncology

He set up, led and developed from scratch the CMR service into one of the largest UK CMR services with a particular focus on the assessment of coronary artery disease. In 2015 he moved to Barts Heart Centre at St Bartholomew’s Hospital where he has jointly formed the largest CMR service in the UK and one of the largest CMR services in Europe. He is also currently developing the new cardio-oncology service at St Bartholomew’s Hospital to ensure the delivery of high quality care to patients cardiovascular disease who also are being treated for cancer.

[Watch Presentation]

Dr. Witteles leads Stanford University’s Cardio-Oncology clinic and is Co-Director of the Stanford Amyloid Center, one of the nation’s largest multidisciplinary groups devoted to amyloidosis. He earned his B.A. at Northwestern University followed by an M.D. with Honors from The University of Chicago Pritzker School of Medicine.

Debater: Type 1 / Type 2 cardiotoxicity is nonsense

He then completed Internal Medicine residency at Stanford University (including an additional year as Chief Resident), followed by fellowship training in Cardiovascular Medicine (including serving as Chief Fellow). Following fellowship, Dr. Witteles joined the faculty at Stanford as a member of the Heart Failure team. Dr. Witteles founded Stanford’s Cardio-Oncology clinic and co-founded the Stanford Amyloid Center in 2008. He has led and collaborated on a multitude of clinical and translational research studies in Cardio-Oncology, amyloidosis, and cardiac sarcoidosis. His other primary role is as Program Director for the Stanford University Internal Medicine residency training program, in which he leads a program of 125 housestaff, and oversees all of the fellowship programs within the Department of Medicine.